What is your current approach to backtranslations outside the EU?

What is your current approach to backtranslations outside the EU?
Pharmaceutical companies take different risk-based approaches whether or not to commission not just forward-, but also backtranslations from a vendor.
This may depend on their local presence in the country where the translation is to be used, their confidence into their vendor, as well as financial and planning aspects.
Thanks for looking at this topic.